Printer Friendly

Research and Markets: An Extensive Analysis of Future Perspectives in Cancer Immunotherapy.

Business Editors

DUBLIN, Ireland--(BUSINESS WIRE)--May 10, 2004

Research and Markets ( has announced the addition of Future Perspectives in Cancer Immunotherapy to their offering.

This report analyses more than 675 industry related cancer immunotherapy R&D projects including more than 425 clinical trials of which 60 are in phase III. The latest meeting held by the American Society of Clinical Oncology, the American Association Cancer Research and the American Society of Hematology are also covered in this extensive analysis.

"Future Perspectives in Cancer Immunotherapy" is a summarized version of our more extensive report "A Shift in Cancer Immunotherapy Strategies?". Still, it provides the essence and main conclusive parts and will work as a guideline for trend analysis, even though the bulk of data which included in the larger report has been removed. If your primary interest is to read the more conclusive and analytical parts, this report is an excellent choice. It provides a broad overview of current efforts in cancer immunotherapy R&D as well as concludes and assesses major factors important for success. Further, it describes the ongoing efforts in developing innovative immunotherapies for the treatment of cancer. Trends within the industry are identified and analyzed.

The contents of this report are structured into several well-defined therapeutic concepts. This includes major therapeutic strategies such as monoclonal antibodies, anti-idiotypic antibodies, tumor antigens, cellular vaccines, gene therapy, immunostimulatory drugs and other biological drugs. The comparison of therapeutic strategies, targets and cancer indications reveals differences between disease and treatment.

The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way. One example is Rituxan, a "drug" that has seen its revenue grow from $152 million in 1998 to more than $1 billion in 2002. Other immune-based therapies that have already reached the market is Zevailn, Bexxar, Campath, OncoVax and Erbitux.

Other cancer vaccine strategies that are on the way are Actimmune, Allovectin-7, Avicine, BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Melacine, Ovarex, Oncophage, Osidem and. These treatments are all FDA approved or in late stage clinical trails. Immunotherapy has for some time been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, there are still a number if missing.

For more information visit
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 10, 2004
Previous Article:Nomura Securities Selects VhaYu's Real-Time and Historic Tick-Data Platform for New Trading Infrastructure in New York.
Next Article:ADVISORY/AAA To Honor School Safety Patrollers for Saving Fellow Students' Lives.

Related Articles
RESEARCHERS DEVELOP CANCER-FIGHTING PROCESS\Technique could boost immune reaction.
Research and Markets: Analysis of Cancer Immunotherapy: Numerous Strategic Possibilities Emerging in Cancer Immunotherapy.
Research and Markets: Antibodies as Cancer Therapeutics - R&D Situation and Business Perspectives.
Research and Markets : This is The Only Product That Provides You with a Comprehensive Picture of the Development of Cancer Vaccines.
Thorough Review of Antibody and Vaccine Delivery and Technologies Surrounding It - The Next Generation.
An Analytical Tool That Will Help You in Identifying Emerging Cancer Immunotherapy Products & Key Areas of Pharmaceutical R&D.
Fierce Competition in Oncology Market as Number of PKIs Rises Sharply.
In-Depth Competitive Landscape Assessment of the Cancer Immunotherapy Market Place.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters